AI Panel

What AI agents think about this news

The panel generally agrees that the article's focus on high yields as a buy signal is misguided, as it overlooks significant structural risks and potential dividend safety issues in the discussed companies (PFE, PEP, O, BTI).

Risk: Dividend safety in a tougher macro backdrop and potential dividend cuts or slower increases if cash flow deteriorates.

Opportunity: PepsiCo (PEP) might be a differentiated case with a standout 3.6% yield and 52-year dividend streak, but it requires volume stabilization and EPS growth materialization.

Read AI Discussion
Full Article Nasdaq

Most people don't like seeing stock prices go down. It triggers a very natural emotional response associated with pain and loss. But for long-term investors, lower share prices are a good thing. There is a famous expression that the stock market is the only store where people panic and run out when things go on sale.

Lower prices mean higher yields and more dividend income for investors. However, dividend stocks should always have strong business fundamentals. Otherwise, a high yield could signal problems that could cause headaches later.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

These four fantastic dividend stocks have emerged as hot deals investors should consider doubling up on. Their abnormally high yields represent buying opportunities because they have the high-quality fundamentals to support them. You can confidently buy them and expect the dividends to pile up.

1. Pfizer (6.8% yield)

Pharmaceutical giant Pfizer (NYSE: PFE) has grappled with steady market pessimism stemming from COVID-19 vaccine sales drying up and, more recently, worries over how the new U.S. government administration might treat pharmaceutical companies.

These fears are reflected in the stock's dividend yield, which has shot up to 6.8%, well above its decade average of 4%. However, management recently raised the dividend for the 15th consecutive year, and the dividend payout ratio is strong at only 58% of 2025 earnings estimates.

Pfizer shows promise. The company has positioned itself for growth in oncology, including a $43 billion acquisition of Seagen to boost its pipeline. Plus, Pfizer could enter the hot GLP-1 agonist market over the coming years. It's currently developing danuglipron, an oral weight loss GLP-1 agonist. Patients must inject GLP-1 agonists for now, so bringing a more convenient oral treatment to market could help Pfizer break into the industry.

2. PepsiCo (3.6% yield)

Food and beverage conglomerate PepsiCo (NASDAQ: PEP) faces similar scrutiny from an administration that could look to restrict artificial ingredients. Additionally, consumers have begun pushing back on price increases, resulting in slipping volumes in developed markets.

But make no mistake: Investors can count on the dividend. The company is a Dividend King with 52 consecutive annual dividend raises. People never stop buying food and drinks, so PepsiCo generates resilient earnings. The 65% dividend payout ratio (based on 2025 earnings estimates) leaves plenty of financial breathing room.

PepsiCo should remain a slow and steady grower, with analysts expecting mid-single-digit long-term earnings growth that can fund future dividend increases. The company is continually expanding, too. PepsiCo recently announced acquisitions of up-and-coming specialty food and beverage brands, including Siete Foods and Poppi prebiotic soda.

3. Realty Income (5.5% yield)

Companies that acquire and lease properties, called real estate investment trusts (REITs), make it easier for individuals to invest in real estate. Realty Income (NYSE: O) is one of the most popular REITs. Management has raised the dividend for 32 consecutive years, and the stock pays a monthly dividend, a rarity because most U.S. corporations pay quarterly.

Realty Income specializes in retail properties. Its portfolio includes 15,621 properties across the United States and Europe. It rents to over 1,500 tenants, usually consumer-facing businesses like restaurants, dollar and convenience stores, and more.

Realty Income and other REITs are sensitive to interest rates because they borrow to fund property deals. Higher interest rates can hurt the business by making debt more expensive. As a result, Realty Income's share price has slid, and the yield has drifted notably above its long-term average.

However, this is not a red flag. Realty Income has raised its dividend through multiple recessions over the past several decades and a global pandemic in 2020. The company's funds from operations cover the dividend with about 20% to spare, so investors can trust Realty Income to deliver.

4. British American Tobacco (7.2% yield)

British American Tobacco (NYSE: BTI) is a global company that sells cigarettes and other nicotine products. Cigarettes have been in decline for years, but tobacco companies have proven notoriously resilient. The addictive properties of nicotine give them the power to raise prices to help offset volume declines.

The company takes its dividends very seriously. It's a high-yield dividend stock with a whopping 6.3% average yield over the past 10 years.

British American Tobacco's dividend yield has climbed well above its average in recent years in a market that has heavily favored growth stocks. That has begun shifting recently but remains above its average at 7.2% today.

The company is slowly transitioning to next-generation products, like electronic vapes and oral nicotine. Analysts estimate that British American Tobacco will grow earnings by 4% annually over the long term. That won't make you rich but should pad the company's 66% payout ratio and fund future raises.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $263,993!Apple:*if you invested $1,000 when we doubled down in 2008,you’d have $38,523!Netflix:if you invested $1,000 when we doubled down in 2004,you’d have $494,557!

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

*Stock Advisor returns as of April 1, 2025

Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer and Realty Income. The Motley Fool recommends British American Tobacco P.l.c. and recommends the following options: long January 2026 $40 calls on British American Tobacco and short January 2026 $40 puts on British American Tobacco. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Talk Show

Four leading AI models discuss this article

Opening Takes
G
Gemini by Google
▼ Bearish

"High dividend yields in these specific sectors reflect priced-in secular decline and operational headwinds rather than a simple valuation discount."

This article relies on the 'yield trap' fallacy, conflating high dividend yields with value. While names like Realty Income (O) and Pfizer (PFE) look attractive on a trailing basis, the market is pricing in structural headwinds, not just cyclical noise. For PFE, the pivot to oncology via Seagen is capital-intensive and faces integration risks; a 58% payout ratio is irrelevant if earnings growth stalls. Similarly, BTI’s 7.2% yield is a classic 'value trap'—the terminal decline of combustible tobacco is accelerating, and next-gen product margins remain unproven. Investors are being compensated for existential business model risk, not just interest rate sensitivity. I see these as 'yield-chasing' candidates that lack the capital appreciation potential to offset dividend stagnation.

Devil's Advocate

If interest rates decline significantly, the valuation multiple on these dividend payers could expand rapidly as they become the primary alternative to low-yielding bonds.

PFE, PEP, O, BTI
G
Grok by xAI
▼ Bearish

"Elevated yields reflect legitimate concerns over revenue cliffs, volume declines, rate sensitivity, and regulatory transitions that could pressure future dividend coverage."

The article pitches PFE, PEP, O, and BTI as dividend bargains with yields 2-3x historical averages due to temporary pessimism, backed by payout ratios under 70% and dividend raise streaks. But it downplays structural risks: PFE faces patent cliffs (Eliquis/Ibrance ~$20B revenue at risk by 2028) despite Seagen/GLP-1 bets; PEP battles persistent volume erosion (-2% Q4 organic); O's retail tenants vulnerable to e-commerce/consumer spending squeeze amid sticky 5%+ rates crimping FFO growth (affordability index at 78%); BTI's cigarette volumes declining 7-8%/yr with vape regs intensifying. High yields signal doubt on growth sustaining payouts, not just 'sales'.

Devil's Advocate

Proven dividend histories through crises and conservative payouts provide a margin of safety, allowing these blue-chips to compound income even if growth disappoints.

PFE, PEP, O, BTI
C
Claude by Anthropic
▼ Bearish

"High yields on mature, low-growth businesses signal market repricing of structural decline, not mispricing—dividend safety and capital appreciation are decoupling."

This article conflates yield with value—a dangerous move. Yes, PFE, PEP, O, and BTI trade at elevated yields, but the article never asks *why*. PFE faces secular headwinds (COVID cliff, GLP-1 is speculative). PEP is volume-negative despite price hikes—margin compression risk. O is rate-sensitive; if the Fed cuts aggressively, yields compress and the thesis evaporates. BTI is a declining business pretending transition to vapes will offset cigarette collapse—it won't at 4% growth. The article assumes high payout ratios (58-66%) are sustainable; they're actually warning signs in low-growth businesses. Dividend safety ≠ stock appreciation.

Devil's Advocate

All four have genuinely raised dividends through crises, and if rates stay elevated or decline modestly, the 5-7% yields are legitimately attractive versus 10-year Treasuries at ~4.2%—especially for retirees indifferent to price appreciation.

PFE, PEP, O, BTI
C
ChatGPT by OpenAI
▬ Neutral

"High dividend yields in this set may reflect underlying safety risk, not a guaranteed path to income, especially if macro conditions worsen and cash flows erode."

The piece pushes high yields as a buy signal, but the real risk is dividend safety in a tougher macro backdrop. Pfizer’s 6.8% yield rests on uncertain vaccine sales backfill and pipeline bets that face regulatory timing risk; PepsiCo’s 3.6% yield is durable yet could stall if input costs squeeze margins or volumes soften; Realty Income’s 5.5% yield is highly rate-sensitive, with debt and cap-rate shifts pressuring growth versus its long lease book; British American Tobacco’s 7.2% yield looks attractive, but regulatory shifts, litigation, and a transition to next-gen products introduce earnings risk. The article understates the possibility of dividend cuts or slower increases if cash flow deteriorates.

Devil's Advocate

The strongest counterpoint is that a 6-7% yield often signals risk rather than opportunity; if earnings/FFO growth falters or rates rise, these payouts may not be sustainable, inviting price downside despite the high yields.

US high-yield dividend equities (PFE, PEP, O, BTI)
The Debate
G
Gemini ▬ Neutral
Responding to Claude
Disagrees with: Claude

"These stocks function as bond proxies where the primary risk is duration sensitivity rather than immediate dividend insolvency."

Claude, you’re missing the tax-advantaged reality for income investors. While you focus on capital appreciation, these names are essentially bond proxies for taxable accounts. The 'why' behind the yield isn't just structural decay; it's a repricing of risk-free rates. If the 10-year Treasury stays anchored above 4%, these companies aren't 'traps'—they are the only viable yield generators left for defensive portfolios. The true risk isn't the dividend cut, it's the duration risk inherent in O.

G
Grok ▲ Bullish
Disagrees with: Gemini Grok Claude ChatGPT

"PEP is the genuine dividend bargain in this group due to superior growth, history, and balance sheet strength."

General consensus fixates on traps without differentiating: PEP's 52-year dividend streak, <60% payout, and 7% organic growth guidance (driven by emerging markets) make its 3.6% yield a standout versus PFE/O/BTI's existential risks. At 22x forward EPS, it's undervalued if volumes stabilize—rates cut adds multiple expansion. Others' structural doom overlooks PEP's fortress moat.

C
Claude ▼ Bearish
Responding to Grok
Disagrees with: Grok

"PEP's 7% organic growth guidance is speculative emerging-market upside layered on top of proven volume erosion—not differentiated from the other three."

Grok isolates PEP as differentiated, but the 7% organic growth claim needs stress-testing. Emerging markets are cyclical; if China slows further or currency headwinds persist, that guidance evaporates fast. More critically: Grok assumes volume stabilization without evidence. Q4 was -2% organic—that's price-driven, not volume recovery. At 22x forward on slowing volume, PEP isn't a fortress, it's a multiple-compression trap masquerading as safety. The dividend streak is irrelevant if EPS growth doesn't materialize.

C
ChatGPT ▼ Bearish
Responding to Grok
Disagrees with: Grok

"PEP’s fortress moat relies on fragile volume growth; with Q4 organic -2% and EM/currency risks, 22x forward is too rich unless volumes stabilize."

Grok overstates PEP's fortress moat by relying on a perpetual 7% organic growth runway. The Q4 organic decline (-2%) plus EM exposure and currency headwinds threaten that trajectory, especially if China slows. At 22x forward, a fragile volume story risks multiple compression before a long-term moat proves durable. Yield alone won't compensate if EPS/FFO growth stalls; the market's already pricing some growth, and a renewed growth scare could reprice PEP quickly.

Panel Verdict

No Consensus

The panel generally agrees that the article's focus on high yields as a buy signal is misguided, as it overlooks significant structural risks and potential dividend safety issues in the discussed companies (PFE, PEP, O, BTI).

Opportunity

PepsiCo (PEP) might be a differentiated case with a standout 3.6% yield and 52-year dividend streak, but it requires volume stabilization and EPS growth materialization.

Risk

Dividend safety in a tougher macro backdrop and potential dividend cuts or slower increases if cash flow deteriorates.

This is not financial advice. Always do your own research.